Integrated Efficacy and Safety Exposure Response (ER) Analysis of Tivozanib (Tivo) for the Treatment of Renal Cell Carcinoma (RCC)
Category: Presentation
Patient-Reported Outcomes (PROs) for Tivozanib + Nivolumab (Tivo-Nivo) vs. Tivozanib (Tivo) Monotherapy in Patients With Renal Cell Carcinoma (RCC) Following an Immune Checkpoint Inhibitor (ICI): Results of the Phase 3 TiNivo-2 Study
Patient-Reported Outcomes (PROs) for Tivozanib + Nivolumab (Tivo-Nivo) vs. Tivozanib (Tivo) Monotherapy in Patients With Renal Cell Carcinoma (RCC) Following an Immune Checkpoint Inhibitor (ICI): Results of the Phase 3 TiNivo-2 Study
ESMO 2024: Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Metastatic Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study
ESMO 2024: Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Metastatic Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study
SITC 2023: FIERCE-HN: A multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/ recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
SITC 2023: FIERCE-HN: A multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/ recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels
CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels
ASCO GU 2023: Estimated cost of adverse event management for patients with metastatic renal cell carcinoma treated with VEGFR TKI
ASCO GU 2023: Estimated cost of adverse event management for patients with metastatic renal cell carcinoma treated with VEGFR TKI
ASCO GI 2023: Final Results of a Phase 1b/2 Study of Tivozanib in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma in Both Previously Untreated Patients and Patients Progressing on Atezolizumab and Bevacizumab
ASCO GI 2023: Final Results of a Phase 1b/2 Study of Tivozanib in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma in Both Previously Untreated Patients and Patients Progressing on Atezolizumab and Bevacizumab
ASCO 2022: Activity of Tivozanib in Non-Clear Cell Renal Cell Carcinoma (nccRCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial
ASCO 2022: Activity of Tivozanib in Non-Clear Cell Renal Cell Carcinoma (nccRCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial
ASCO 2022: Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up
ASCO 2022: Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up
ASCO GU 2022: TiNivo-2: A Phase 3, Randomized, Controlled, Open-Label Study to Compare Tivozanib in Combo With Nivolumab to Tivozanib Monotherapy in Patients With RCC Following 1 or 2 Lines of Therapy in Which at Least One Line Has an Immune CPI
ASCO GU 2022: TiNivo-2: A Phase 3, Randomized, Controlled, Open-Label Study to Compare Tivozanib in Combo With Nivolumab to Tivozanib Monotherapy in Patients With RCC Following 1 or 2 Lines of Therapy in Which at Least One Line Has an Immune CPI